Scarica l'app Stockscreener
2.62
0.00%
0.00
Pre-mercato:
2.64
0.02
+0.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.62
Aprire:
$2.56
Volume 24 ore:
3.82M
Relative Volume:
0.78
Capitalizzazione di mercato:
$672.84M
Reddito:
$403.14M
Utile/perdita netta:
$-22.68M
Rapporto P/E:
-12.51
EPS:
-0.2095
Flusso di cassa netto:
$-13.09M
1 W Prestazione:
-3.32%
1M Prestazione:
-20.61%
6M Prestazione:
+7.82%
1 anno Prestazione:
+50.57%
Intervallo 1D:
$2.48
$2.64
Intervallo di 1 settimana:
$2.43
$2.675
Portata 52W:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.62 | 672.84M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion acquires Enbumyst maker Corstasis - MSN
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics prices $75M public offering - MSN
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Insider Monkey
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock - MarketBeat
Esperion Therapeutics CFO Halladay sells $17k in stock By Investing.com - Investing.com India
Esperion Therapeutics CEO Koenig sells $69,546 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Halladay sells $17k in stock - Investing.com
Esperion (NASDAQ: ESPR) CLO sells 5,708 shares to cover RSU tax bill - Stock Titan
Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CFO sells shares to cover taxes on vested RSUs - Stock Titan
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 7.6%Here's What Happened - MarketBeat
Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
ESPR (NASDAQ: ESPR) affiliate files to sell 6,424 vested shares after vesting - Stock Titan
ESPR (NASDAQ: ESPR) Form 144 files planned sale of 5,708 shares - Stock Titan
Sheldon Koenig to sell 25,578 ESPR shares (NASDAQ: ESPR) under Form 144 - Stock Titan
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - Bitget
Esperion to Present Two New Analyses From CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - 富途牛牛
CLEAR Outcomes trial findings to be presented by Esperion Therapeutics at major cardiology event - Traders Union
Bempedoic acid data spotlight statin-intolerant, autoimmune patients - Stock Titan
BofA reiterates Esperion Therapeutics stock Underperform rating By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) CFO receives major equity grants - Stock Titan
Esperion (ESPR) CLO receives new stock and option grants - Stock Titan
[Form 4] Esperion Therapeutics, Inc. In... - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 7.8% Following Analyst Upgrade - MarketBeat
2026 cholesterol guideline backs bempedoic acid for statin-intolerant patients - Stock Titan
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - Sahm
Operating cash flow per share of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference - MarketBeat
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Integral Health Asset Management LLC Purchases New Stake in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics (NASDAQ:ESPR) Price Target Raised to $5.00 - MarketBeat
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - TradingView
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
Esperion Therapeutics Q4 2025 earnings preview - MSN
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):